These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10996949)

  • 21. Medicare Spending on Brand-name Combination Medications vs Their Generic Constituents.
    Sacks CA; Lee CC; Kesselheim AS; Avorn J
    JAMA; 2018 Aug; 320(7):650-656. PubMed ID: 30140875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Substitution of generic for brand medicines in primary care. Factors associated to refuse the change].
    Sagardui-Villamor JK; Lacalle Rodríguez-Labajo M; Casado-Buendía S
    Aten Primaria; 2005 Nov; 36(9):489-93. PubMed ID: 16324506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Societal value of generic medicines beyond cost-saving through reduced prices.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):701-11. PubMed ID: 25695926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Generic medicines].
    Peláez de Loño J
    Rev Enferm; 1999 Dec; 22(12):836-43. PubMed ID: 10797771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do generics offer significant savings to the UK National Health Service?
    Kanavos P
    Curr Med Res Opin; 2007 Jan; 23(1):105-16. PubMed ID: 17257472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The impact of an intervention strategy in the prescription of generic drugs in a primary care area].
    Calvo Alcántara MJ; Iñesta García A
    Aten Primaria; 1999 Apr; 23(7):419-24. PubMed ID: 10363394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluating, improving and monitoring generic drug prescription].
    López-Picazo Ferrer JJ; Sanz Moreno JA; Bernal Montañés JM; Sánchez Ruiz JF
    Aten Primaria; 2002 Apr; 29(7):397-406. PubMed ID: 12031234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New mechanism to identify cost savings in English NHS prescribing: minimising 'price per unit', a cross-sectional study.
    Croker R; Walker AJ; Bacon S; Curtis HJ; French L; Goldacre B
    BMJ Open; 2018 Feb; 8(2):e019643. PubMed ID: 29439078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of regulatory measures on antipsychotics drug consumption in Castilla y León, Spain.
    Martín Arias LH; Treceño Lobato C; Pérez García S; García Ortega P; Sáinz Gil M; Sanz Fadrique R; Carvajal García-Pando A
    Public Health; 2016 Dec; 141():113-119. PubMed ID: 27931985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of drug consumption with indicators of prescription quality].
    Gómez Juanes V; Candás Villar MA; Fidalgo González S; Armesto Gómez J; Calvo Alcántara MJ; de Marino Gómez-Sandoval MA; Vicens Caldentey C
    Aten Primaria; 2000 May; 25(9):618-24. PubMed ID: 10920515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability.
    Dylst P; Vulto AG; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2014 Jun; 14(3):345-53. PubMed ID: 24758569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of hypolipemic agents in Spain, 1987-2000].
    Siles Gutiérrez M; Goldaracena Tanco M; Avila Muñoz L; Sánchez-Eznarriaga BC
    Rev Esp Salud Publica; 2001; 75(2):129-41. PubMed ID: 11400423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Do generic drugs help control expenditure on hypertension? Apropos of a case].
    García AJ; Martos F; Martín A; Sánchez F
    Gac Sanit; 2004; 18(2):137-44. PubMed ID: 15104975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attitudes of Slovene general practitioners towards generic drug prescribing and comparison with international studies.
    Kersnik J; Peklar J
    J Clin Pharm Ther; 2006 Dec; 31(6):577-83. PubMed ID: 17176362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficiency in the prescription of drugs. Impact of a health policy: automatic change to prescription by active ingredient].
    López de Landache IE; Braceras Izaguirre L; Echeto García A; Gardeazabal Romillo MJ; Acevedo Heranz P
    Rev Enferm; 2013 Nov; 36(11):49-52. PubMed ID: 24404717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Generic Competition on Atorvastatin Prescribing and Patients' Out-of-Pocket Spending.
    Luo J; Seeger JD; Donneyong M; Gagne JJ; Avorn J; Kesselheim AS
    JAMA Intern Med; 2016 Sep; 176(9):1317-23. PubMed ID: 27367749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.
    Haas JS; Phillips KA; Gerstenberger EP; Seger AC
    Ann Intern Med; 2005 Jun; 142(11):891-7. PubMed ID: 15941695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.
    Gumbs PD; Verschuren WM; Souverein PC; Mantel-Teeuwisse AK; de Wit GA; de Boer A; Klungel OH
    Br J Clin Pharmacol; 2007 Nov; 64(5):680-5. PubMed ID: 17875197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.